Biosimilars: Implications for health-system pharmacists.

Area of Science:

• Biopharmaceutical development
• Regulatory science
• Health economics

Background:

• Biosimilar products are highly similar versions of approved biological drugs.
• The U.S. is establishing an expedited approval pathway for biosimilars, mirroring European Union practices.
• The Food and Drug Administration (FDA) has issued draft guidance for biosimilar approval.

Purpose of the Study:

• To provide an update on scientific and regulatory challenges in biosimilar product development.
• To highlight the expected expansion of the U.S. biosimilar market.
• To inform health systems about preparing for biosimilar integration.

Main Methods:

• Review of current scientific and regulatory landscape for biosimilars.
• Analysis of FDA guidance and market trends.
• Discussion of potential implications for healthcare systems.

Main Results:

• The U.S. biosimilar market is poised for growth with an established approval pathway.
• Manufacturing changes can impact biosimilar safety and efficacy.
• Interchangeability and indication approval may present initial challenges.
• Anticipated pharmaceutical cost savings range from 20-30%.

Conclusions:

• Biosimilars offer opportunities to manage pharmaceutical expenditures.
• Pharmacists are crucial in preparing health systems for biosimilar adoption.
• Addressing formulary management, pharmacovigilance, and patient safety is essential.